Evaluation of the Effect of AZD5069 in Patients with Bronchiectasis - STRATUS

Exclusion Criteria

• - Any clinically significant disease or disorder
• - Patients with other latent or chronic infections or at risk of infection within 90 days before Visit 2
• - An acute exacerbation or acute respiratory infection (upper or lower) requiring oral steroids or antibiotics within 30 days prior to Visit 2
• - An FEV1 of <30% of predicted normal at Visit 1
• - Patients who have received live or live-attenuated vaccine in the 2 weeks prior to dosing (Visit 2)
• - Concomitant diagnosis of significant pulmonary disease other than bronchiectasis or COPD, including symptomatic asthma and allergic bronchopulmonary aspergillosis
• - Bronchiectasis associated with a generalised immunodeficiency disorder, where manifestations other than bronchiectasis predominate